Cargando…
Converting Treatment Plans From Helical Tomotherapy to L-Shape Linac: Clinical Workflow and Dosimetric Evaluation
This work evaluated a commercial fallback planning workflow designed to provide cross-platform treatment planning and delivery. A total of 27 helical tomotherapy intensity-modulated radiotherapy plans covering 4 anatomical sites were selected, including 7 brain, 5 unilateral head and neck, 5 bilater...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048611/ https://www.ncbi.nlm.nih.gov/pubmed/29986638 http://dx.doi.org/10.1177/1533033818785279 |
_version_ | 1783340128427573248 |
---|---|
author | Yuan, Zilong Nair, Chithra Kumaran Benedict, Stanley H. Valicenti, Richard K. Rao, Shyam Fragoso, Ruben C. Wright, Cari Qiu, Jianfeng Rong, Yi |
author_facet | Yuan, Zilong Nair, Chithra Kumaran Benedict, Stanley H. Valicenti, Richard K. Rao, Shyam Fragoso, Ruben C. Wright, Cari Qiu, Jianfeng Rong, Yi |
author_sort | Yuan, Zilong |
collection | PubMed |
description | This work evaluated a commercial fallback planning workflow designed to provide cross-platform treatment planning and delivery. A total of 27 helical tomotherapy intensity-modulated radiotherapy plans covering 4 anatomical sites were selected, including 7 brain, 5 unilateral head and neck, 5 bilateral head and neck, 5 pelvis, and 5 prostate cases. All helical tomotherapy plans were converted to 7-field/9-field intensity-modulated radiotherapy and volumetric-modulated radiotherapy plans through fallback dose-mimicking algorithm using a 6-MV beam model. The planning target volume (PTV) coverage (D (1), D (99), and homogeneity index) and organs at risk dose constraints were evaluated and compared. Overall, all 3 techniques resulted in relatively inferior target dose coverage compared to helical tomotherapy plans, with higher homogeneity index and maximum dose. The organs at risk dose ratio of fallback to helical tomotherapy plans covered a wide spectrum, from 0.87 to 1.11 on average for all sites, with fallback plans being superior for brain, pelvis, and prostate sites. The quality of fallback plans depends on the delivery technique, field numbers, and angles, as well as user selection of structures for organs at risk. In actual clinical scenario, fallback plans would typically be needed for 1 to 5 fractions of a treatment course in the event of machine breakdown. Our results suggested that <1% dose variance can be introduced in target coverage and/or organs at risk from fallback plans. The presented clinical workflow showed that the fallback plan generation typically takes 10 to 20 minutes per case. Fallback planning provides an expeditious and effective strategy for transferring patients cross platforms, and minimizing the untold risk of a patient missing treatment(s). |
format | Online Article Text |
id | pubmed-6048611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60486112018-07-20 Converting Treatment Plans From Helical Tomotherapy to L-Shape Linac: Clinical Workflow and Dosimetric Evaluation Yuan, Zilong Nair, Chithra Kumaran Benedict, Stanley H. Valicenti, Richard K. Rao, Shyam Fragoso, Ruben C. Wright, Cari Qiu, Jianfeng Rong, Yi Technol Cancer Res Treat Original Article This work evaluated a commercial fallback planning workflow designed to provide cross-platform treatment planning and delivery. A total of 27 helical tomotherapy intensity-modulated radiotherapy plans covering 4 anatomical sites were selected, including 7 brain, 5 unilateral head and neck, 5 bilateral head and neck, 5 pelvis, and 5 prostate cases. All helical tomotherapy plans were converted to 7-field/9-field intensity-modulated radiotherapy and volumetric-modulated radiotherapy plans through fallback dose-mimicking algorithm using a 6-MV beam model. The planning target volume (PTV) coverage (D (1), D (99), and homogeneity index) and organs at risk dose constraints were evaluated and compared. Overall, all 3 techniques resulted in relatively inferior target dose coverage compared to helical tomotherapy plans, with higher homogeneity index and maximum dose. The organs at risk dose ratio of fallback to helical tomotherapy plans covered a wide spectrum, from 0.87 to 1.11 on average for all sites, with fallback plans being superior for brain, pelvis, and prostate sites. The quality of fallback plans depends on the delivery technique, field numbers, and angles, as well as user selection of structures for organs at risk. In actual clinical scenario, fallback plans would typically be needed for 1 to 5 fractions of a treatment course in the event of machine breakdown. Our results suggested that <1% dose variance can be introduced in target coverage and/or organs at risk from fallback plans. The presented clinical workflow showed that the fallback plan generation typically takes 10 to 20 minutes per case. Fallback planning provides an expeditious and effective strategy for transferring patients cross platforms, and minimizing the untold risk of a patient missing treatment(s). SAGE Publications 2018-07-09 /pmc/articles/PMC6048611/ /pubmed/29986638 http://dx.doi.org/10.1177/1533033818785279 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Yuan, Zilong Nair, Chithra Kumaran Benedict, Stanley H. Valicenti, Richard K. Rao, Shyam Fragoso, Ruben C. Wright, Cari Qiu, Jianfeng Rong, Yi Converting Treatment Plans From Helical Tomotherapy to L-Shape Linac: Clinical Workflow and Dosimetric Evaluation |
title | Converting Treatment Plans From Helical Tomotherapy to L-Shape Linac:
Clinical Workflow and Dosimetric Evaluation |
title_full | Converting Treatment Plans From Helical Tomotherapy to L-Shape Linac:
Clinical Workflow and Dosimetric Evaluation |
title_fullStr | Converting Treatment Plans From Helical Tomotherapy to L-Shape Linac:
Clinical Workflow and Dosimetric Evaluation |
title_full_unstemmed | Converting Treatment Plans From Helical Tomotherapy to L-Shape Linac:
Clinical Workflow and Dosimetric Evaluation |
title_short | Converting Treatment Plans From Helical Tomotherapy to L-Shape Linac:
Clinical Workflow and Dosimetric Evaluation |
title_sort | converting treatment plans from helical tomotherapy to l-shape linac:
clinical workflow and dosimetric evaluation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048611/ https://www.ncbi.nlm.nih.gov/pubmed/29986638 http://dx.doi.org/10.1177/1533033818785279 |
work_keys_str_mv | AT yuanzilong convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation AT nairchithrakumaran convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation AT benedictstanleyh convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation AT valicentirichardk convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation AT raoshyam convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation AT fragosorubenc convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation AT wrightcari convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation AT qiujianfeng convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation AT rongyi convertingtreatmentplansfromhelicaltomotherapytolshapelinacclinicalworkflowanddosimetricevaluation |